» Articles » PMID: 14987333

Validation of a General Measure of Treatment Satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), Using a National Panel Study of Chronic Disease

Overview
Publisher Biomed Central
Specialty Public Health
Date 2004 Feb 28
PMID 14987333
Citations 412
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The objective of this study was to develop and psychometrically evaluate a general measure of patients' satisfaction with medication, the Treatment Satisfaction Questionnaire for Medication (TSQM).

Methods: The content and format of 55 initial questions were based on a formal conceptual framework, an extensive literature review, and the input from three patient focus groups. Patient interviews were used to select the most relevant questions for further evaluation (n = 31). The psychometric performance of items and resulting TSQM scales were examined using eight diverse patient groups (arthritis, asthma, major depression, type I diabetes, high cholesterol, hypertension, migraine, and psoriasis) recruited from a national longitudinal panel study of chronic illness (n = 567). Participants were then randomized to complete the test items using one of two alternate scaling methods (Visual Analogue vs. Likert-type).

Results: A factor analysis (principal component extraction with varimax rotation) of specific items revealed three factors (Eigenvalues > 1.7) explaining 75.6% of the total variance; namely Side effects (4 items, 28.4%, Cronbach's Alpha =.87), Effectiveness (3 items, 24.1%, Cronbach's Alpha =.85), and Convenience (3 items, 23.1%, Cronbach's Alpha =.87). A second factor analysis of more generally worded items yielded a Global Satisfaction scale (3 items, Eigenvalue = 2.3, 79.1%, Cronbach's Alpha =.85). The final four scales possessed good psychometric properties, with the Likert-type scaling method performing better than the VAS approach. Significant differences were found on the TSQM by the route of medication administration (oral, injectable, topical, inhalable), level of illness severity, and length of time on medication. Regression analyses using the TSQM scales accounted for 40-60% of variation in patients' ratings of their likelihood to persist with their current medication.

Conclusion: The TSQM is a psychometrically sound and valid measure of the major dimensions of patients' satisfaction with medication. Preliminary evidence suggests that the TSQM may also be a good predictor of patients' medication adherence across different types of medication and patient populations.

Citing Articles

Benefits and Satisfaction with Apremilast Treatment in Patients with Psoriasis Affecting the Genital Area: Secondary Analysis of the APPRECIATE Study.

da Silva Burger N, Tran K, Typou M, Sommer R, Neasham D, Cordey M Dermatol Ther (Heidelb). 2025; 15(3):681-695.

PMID: 39969771 DOI: 10.1007/s13555-025-01360-y.


Protocol of an open-label safety and feasibility pilot study of ketamine-assisted psychotheray for methamphetamine use disorder (the KAPPA trial).

Fletcher K, Ezard N, Siefried K, MacDonald H, Acheson L, Bedi G BMJ Open. 2025; 15(2):e092504.

PMID: 39929500 PMC: 11815421. DOI: 10.1136/bmjopen-2024-092504.


Trial protocol of an open-label pilot study of oral ltrexone-propion combination pharmacotherapy for the treatment of methamphetamine use disorder (the NABU trial).

Siefried K, Acheson L, Clifford B, Moller C, Brett J, Christmass M BMJ Open. 2025; 15(2):e092032.

PMID: 39920060 PMC: 11808914. DOI: 10.1136/bmjopen-2024-092032.


Treatment satisfaction and patient reported outcomes among people with opioid use disorder participating in an open-label, non-randomised trial of long-acting injectable buprenorphine treatment in Australian custodial settings.

White B, Little S, Haber P, Roberts J, Nolan E, Lintzeris N Drug Alcohol Rev. 2025; 44(2):640-648.

PMID: 39901317 PMC: 11814349. DOI: 10.1111/dar.14005.


A randomised double-blind, placebo-controlled trial of pramipexole in addition to mood stabilisers for patients with treatment-resistant bipolar depression (the PAX-BD study).

McAllister-Williams R, Goudie N, Azim L, Bartle V, Berger M, Butcher C J Psychopharmacol. 2025; 39(2):106-120.

PMID: 39829389 PMC: 11831867. DOI: 10.1177/02698811241309622.


References
1.
McCracken L, Klock P, Mingay D, Asbury J, Sinclair D . Assessment of satisfaction with treatment for chronic pain. J Pain Symptom Manage. 1997; 14(5):292-9. DOI: 10.1016/s0885-3924(97)00225-x. View

2.
Bradley C . Diabetes treatment satisfaction questionnaire. Change version for use alongside status version provides appropriate solution where ceiling effects occur. Diabetes Care. 1999; 22(3):530-2. DOI: 10.2337/diacare.22.3.530. View

3.
Borner M, Schoffski P, de Wit R, Caponigro F, Comella G, Sulkes A . Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer. 2002; 38(3):349-58. DOI: 10.1016/s0959-8049(01)00371-9. View

4.
Lin B, Kelly E . Methodological issues in patient satisfaction surveys. Int J Health Care Qual Assur. 1994; 8(6):32-7. DOI: 10.1108/09526869510098840. View

5.
Albrecht G, Hoogstraten J . Satisfaction as a determinant of compliance. Community Dent Oral Epidemiol. 1998; 26(2):139-46. DOI: 10.1111/j.1600-0528.1998.tb01940.x. View